Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
XINT.STthis companyXintela AB (publ)	SEK 0.14	-4.03×	-37.15×	85.84×	-4.18×	-91.2%	73.4%	-2045.7%	-2128.1%	921.0%	-306.9%	-21.2%	-3.79×	0.07×	-13.39×	0.84×	0.0%	2	-22.87	2	C
ACARIX.STAcarix AB (publ)	SEK 0.16	-6.28×	7.91×	41.02×	-6.37×	-225.0%	37.5%	-652.2%	-653.3%	-126.0%	-125.8%	-16.3%	0×	0.41×	0×	4.08×	0.0%	3	12.43	1	D+
ACE.STAscelia Pharma AB (publ)	SEK 0.54	-4.81×	3.67×	0×	-4.32×	-17.7%	0.0%	0.0%	0.0%	-76.7%	-73.4%	-19.8%	0.01×	0.67×	-13.46×	4.35×	0.0%	1	-8.91	2	C+
BIOWKS.STBio-Works Technologies AB (publ)	SEK 3.17	-15.41×	4.64×	3.66×	-11.76×	-1411.9%	76.5%	-28.0%	-24.4%	-31.0%	-31.6%	-8.4%	0×	2.12×	-90.77×	3.2×	0.0%	4	16.39	2	C
ELIC.STElicera Therapeutics AB (publ)	SEK 2.60	-13.74×	10.19×	0×	-12.25×	-80.7%	0.0%	0.0%	0.0%	-74.5%	-76.8%	-9.1%	0×	1.43×	-2,278.11×	6.75×	0.0%	1	32.08	1	C-
IMMU.STMendus AB (publ)	SEK 5.23	-2.58×	0.5×	0×	-2.16×	-84.5%	0.0%	0.0%	0.0%	-19.4%	-19.9%	-28.0%	0.03×	0.4×	-36.63×	2.7×	0.0%	1	-0.16	2	B-
Peer median	—	-6.28×	4.64×	0×	-6.37×	-84.5%	0.0%	0.0%	0.0%	-74.5%	-73.4%	-16.3%	0×	0.67×	-36.63×	4.08×	0.0%	1	12.43	2	—